Marik P E, Varon J
MICU, St. Vincent Hospital, University of Massachusetts Medical School, Worcester 01604, USA.
Chest. 1998 Sep;114(3):854-60. doi: 10.1378/chest.114.3.854.
The incidence of the sepsis syndrome has increased dramatically in the last few decades. During this time, we have gained new insights into the pathophysiologic mechanisms leading to organ dysfunction in this syndrome. Yet, despite this increased knowledge and the use of novel therapeutic approaches, the mortality associated with the sepsis syndrome has remained between 30% and 40%. Appropriate antibiotic selection and hemodynamic support remain the cornerstone of treatment of patients with sepsis. Recent studies have failed to demonstrate a global oxygen debt in patients with sepsis. Furthermore, therapy aimed at increasing systemic oxygen delivery has failed to consistently improve patient outcome. The primary aim of the initial phase of resuscitation is to restore an adequate tissue perfusion pressure. Aggressive volume resuscitation is considered the best initial therapy for the cardiovascular instability of sepsis. Vasoactive agents are required in patients who remain hemodynamically unstable or have evidence of tissue hypoxia after adequate volume resuscitation.
在过去几十年中,脓毒症综合征的发病率急剧上升。在此期间,我们对导致该综合征器官功能障碍的病理生理机制有了新的认识。然而,尽管有了这些更多的认识并采用了新的治疗方法,但与脓毒症综合征相关的死亡率仍保持在30%至40%之间。恰当的抗生素选择和血流动力学支持仍然是脓毒症患者治疗的基石。最近的研究未能证实在脓毒症患者中存在全身性氧债。此外,旨在增加全身氧输送的治疗未能持续改善患者的预后。复苏初始阶段的主要目标是恢复足够的组织灌注压。积极的容量复苏被认为是治疗脓毒症心血管不稳定的最佳初始疗法。对于在充分容量复苏后仍存在血流动力学不稳定或有组织缺氧证据的患者,需要使用血管活性药物。